What is Austedo’s (deutetrabenazine) pharmacokinetic profile?
Austedo (deutetrabenazine) is designed for once- or twice-daily dosing depending on the indication. Its pharmacokinetics are driven by its active metabolites—primarily deutetrabenazine-derived forms—rather than the parent drug. After dosing, the active metabolites reach peak concentrations within a few hours and then decline, with exposure that generally increases with dose. The overall PK behavior supports the product’s staged dosing schedules and dose adjustments based on tolerability.
How does Austedo absorption and time-to-peak work?
After oral administration, deutetrabenazine is absorbed and converted to active metabolites. Drug exposure rises to maximum levels after several hours, then falls over time as the metabolites are cleared. This time course is part of why dosing is scheduled to maintain therapeutic metabolite concentrations over the dosing interval.
How is Austedo metabolized and eliminated?
Austedo undergoes metabolic conversion in the body into its active forms, which are then cleared primarily through hepatic metabolism pathways. The key pharmacokinetic point for patients and prescribers is that both metabolism and clearance can be affected by liver function and some interacting drugs, which is why dose selection and interaction checks matter.
What are the key factors that can change Austedo exposure (dose, liver status, drug interactions)?
Austedo exposure can be altered by:
- Liver impairment, which can change metabolite clearance and increase drug exposure.
- Co-medications that affect metabolic enzymes or transport processes involved in deutetrabenazine metabolite handling.
These factors can lead to higher concentrations and increased risk of adverse effects, so dose adjustments and careful review of other medications are central to safe use.
How does Austedo PK compare with similar VMAT2 inhibitors?
Austedo (deutetrabenazine) is related to tetrabenazine (another VMAT2 inhibitor), and differences in formulation and metabolism contribute to different dosing schedules and metabolite exposure patterns. Patients switching between VMAT2 inhibitors typically require attention to dose-equivalence and titration because the exposure and clinical effect timing can differ.
Where can I find detailed Austedo pharmacokinetic data (Cmax, Tmax, half-life)?
For detailed pharmacokinetic parameters such as Cmax, Tmax, apparent half-life, and exposure metrics, check the prescribing information for Austedo. DrugPatentWatch.com also tracks regulatory and patent documentation that can point you to the relevant label sections and related materials. See Austedo coverage on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/drug/austedo/
Sources
- https://www.drugpatentwatch.com/p/drug/austedo/